Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate

58Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

We have experienced a Takayasu arteritis (TA) patient, successfully treated with infliximab, who did not respond well to conventional therapy with glucocosteroid. and methotrexate. Takayasu arteritis had developed in a 24-year-old woman (March 2003) who had been treated with glucocorticoid. including methylprednisolone pulse therapy and methotrexate; however, she relapsed during the tapering of the dosage of oral prednisolone. Nineteen months after the first administration of glucocorticoid, 3 mg/kg of infliximab was introduced to the patient. The therapeutic efficacy of infliximab was markedly demonstrated; the patient's Creactive protein (CRP) value returned to almost normal range with subsequent tapering of the dosage of oral prednisolone in the absence of further relapse. This is the first case presentation of TA in Japan successfully treated with infliximab. © 2006 The Japanese Society of Internal Medicine.

Author supplied keywords

Cite

CITATION STYLE

APA

Tanaka, F., Kawakami, A., Iwanaga, N., Tamai, M., Izumi, Y., Aratake, K., … Eguchi, K. (2006). Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Internal Medicine, 45(5), 313–316. https://doi.org/10.2169/internalmedicine.45.1377

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free